Skip to Content

  • Search

View Additional Section Content

B-55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT02032823?term=NCT02032823&rank=1

Principal Investigator(s)
Willard G. Andrews III, MD

Clinical Trial Categories

  • Breast Cancer
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details